Post-earnings recap
Reported
Tue, Feb 20, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Ultragenyx's earnings report showed a smaller-than-expected loss per share, which contributed to a positive stock reaction, with shares rising by 2.25%. The lack of revenue data makes it challenging to assess overall performance, but management's focus on their pipeline suggests potential future growth. Investors may view the EPS beat as a sign of operational efficiency.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.89 | N/A | +4.92% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a cautious optimism about the company's direction. They emphasized the significance of their research and development efforts.
Management expressed confidence in the company's ongoing projects and pipeline.
They highlighted the importance of upcoming clinical trials for future growth.